Qiagen Nv

QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook

QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026

QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel

Bruker Announces Appointment of Thierry Bernard to its Board of Directors

Parse Biosciences, a QIAGEN Company, Launches FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis